Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Sono Tek Corp filings on SEC EDGAR ↗
Sonotech delivered solid H1 FY2027 results with 6% revenue growth and significant margin expansion, driven by a strategic shift toward high-value medical production systems and record-breaking alternative energy orders.
Sono-Tek Corporation reported a 6% increase in net sales to $10.89 million for the six months ended August 31, 2026, compared to the prior year. Net income grew to $1.11 million, driven by improved gross margins and higher interest income, despite an increase in operating expenses and a net unrealized loss on marketable securities.
Sono-Tek reported fiscal second quarter 2027 results with net sales of $5.23 million and net income of $366,000. For the first half of the fiscal year, revenue increased 6% to $10.89 million, driven by a 289% surge in medical market sales. The company reiterated its full-year guidance for flat to modest revenue growth due to the timing of large orders.
Term
Q2 2027
“Fiscal 2027 is progressing well, with solid first-half revenue growth, meaningful gross margin expansion and strong improvement in operating profitability. These results reflect disciplined execution across our operations and continued progress with our strategy of focusing on higher-value production systems in advanced technology markets, particularly medical devices.”
Steve Harshbarger, President and Chief Executive Officer